BICO consists of several subsidiaries organized into three business areas. Together, we aim to reduce the world’s organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology.
We’re equipping hundreds of labs and thousands of scientists worldwide with cutting-edge technologies that fuel groundbreaking scientific breakthroughs.
Converging for multiple speed
In December 2022, The U.S. Congress passed the FDA Modernization Act 2.0. This means that animal testing will no longer be required for market approval.
A historic milestone in the acceptance of alternatives to animal models in drug discovery. Alternatives that capture human physiology better, that are more ethical, sustainable and most importantly can accelerate the discovery of life changing therapies.